No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Yiqiao Shenzhou (301047.SZ): Yiqiao Taizhou has been recognized as a high-tech enterprise.
Glory Financial reported on February 19 that Yiqiao Shenzhou (301047.SZ) announced that its wholly-owned subsidiary Yiqiao Shenzhou (Taizhou) Technology Co., Ltd. (abbreviated as "Yiqiao Taizhou") recently received the "High-tech Enterprise Certificate" issued jointly by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the State Taxation Administration Jiangsu Provincial Taxation Bureau.
Yiqiao Shenzhou (301047.SZ): The company's products and services are mainly applied to support the research work of research Institutions and Biomedical companies, and are not formulated medicines, thus not used for clinical treatment.
On February 10, Gelonghui reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that the company possesses a globally leading influenza reagent research library, providing important research reagents and technical support for pharmaceutical companies and other clients. As of now, the company's influenza reagent library includes H1N1, H3N2, H5N1, and other subtype influenza viruses, covering seasonal flu, Bird Flu, and other categories. The company's products and services are primarily applied to support the research work of Institutions and Biomedical companies, not for drug formulation or clinical treatment.
Yiqiao Shenzhou (301047.SZ): The Suzhou subsidiary has launched new products such as salt-loving nucleases and linker enzymes.
On February 10, Gelonghui reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that its subsidiary in Suzhou has launched new products such as salt-loving nucleases and linkage enzymes. The analysis and testing service Business has successfully completed on-site audits for multiple clients and has started taking on various testing projects, with the Business steadily developing.
Yiqiao Shenzhou (301047.SZ): The total number of spot products produced and sold exceeds 74,000 varieties.
On February 10, Glory Exchange reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that the company produces and sells a total of over 74,000 types of spot products, including over 9,000 types of recombinant proteins, more than 14,000 types of antibodies, and over 0.05 million types of genes and high-performance serum-free culture medium series products, which can cover multiple fields of life science research, providing a "one-stop" procurement channel for biological reagent products and technical services for basic research directions such as molecular biology, cell biology, immunology, developmental biology, and stem cell research, as well as for the development of Innovative Drugs.
Yiqiao Shenzhou (301047.SZ): Customers include international pharmaceutical companies such as Roche, Pfizer, Sanofi, and others.
On February 10th, Gelonghui reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that the company has been deeply engaged in the field of biological reagents for many years, gradually establishing relatively stable partnerships with clients, forming a good market reputation. Clients include internationally renowned pharmaceutical companies such as Roche, Pfizer, and Sanofi.
Are Poor Financial Prospects Dragging Down Sino Biological,Inc. (SZSE:301047 Stock?